News

NIH's MERS vaccine looks promising in mice

Investigators at the NIH have developed a new MERS vaccine that looks promising in mice. Focusing on the structure of a viral protein that the MERS virus uses to enter cells, the researchers developed a two-step, prime-boost process.

Sanofi's dengue vax protects two-thirds of people aged 9 and up: NEJM

As it works to introduce its dengue vaccine in endemic countries around the world, Sanofi Pasteur this week touted efficacy results from two Phase III studies in a move to help build the case for wide uptake.

GSK envisions 'thoughtful, staged rollout' for Mosquirix

GlaxoSmithKline's malaria jab got the green light from the EMA on Friday and the British pharma is making plans for a gradual rollout of the vaccine.

Pfizer's U.S. Prevnar 13 sales jump 87% in Q2

The world's biggest vaccine by sales--Prevnar 13--just keeps getting bigger. And in doing so, the shot helped Pfizer notch 44% vaccines growth for the second quarter as the unit saw sales grow from $1.09 billion in last year's Q2 to $1.58 billion during the period this year.

Bavarian Nordic starts PhII of Prostvac in early-stage cancer

Looking to expand its potential market for prostate cancer immunotherapy candidate Prostvac, Bavarian Nordic has announced that it's beginning a Phase II trial for its vaccine in early-stage prostate cancer, representing another possible avenue to broaden the candidate's reach.

Glaxo's malaria vaccine gets EMA green light

GlaxoSmithKline's malaria vaccine, RTS,S or Mosquirix, has won a positive opinion from the EMA's Committee for Medicinal Products for Human Use for use in children aged 6 weeks to 17 months outside the European Union, the agency said in a statement.

SutroVax bags $22M Series A to develop vaccines for infectious diseases

SutroVax, the vaccine spinoff from Fierce 15 honoree Sutro Biopharma that is developing vaccines for infectious diseases, announced Thursday the completion of a $22 million Series A financing.

NIAID scientists one step closer to 'universal' flu vaccine

A vaccine against a wide range of flu viruses has long eluded scientists, but NIAID researchers have discovered what could be the foundation of a 'universal' flu vaccine.

Health officials detail need for $2B vaccines fund

In an effort to bridge the financial gap between early stage drug discovery work and late stage development, health officials this week called for the formation of a $2 billion fund to aid vaccine research against deadly diseases such as Ebola, MERS and West Nile virus. 

Pfizer talks up 'comprehensive' vaccines business

Though it can boast its ownership of the world's bestselling vaccine in Prevnar, Pfizer is not stopping there. On Tuesday, the New York City-based pharma unveiled details of its effort to build out its vaccines business by researching a range of conditions from birth until old age.

Novavax's Ebola vaccine shows promise in PhI

Back in February, Novavax took its Ebola candidate to Australia for a Phase I trial. The company reported positive top-line results from the 230-person trial on Tuesday.

Sanofi's dengue vaccine anticipated on profitability 'high end'

With its largest ever investment in a vaccine at stake, Sanofi is in the midst of rolling out the dengue fever vaccine it's worked on for 20 years at a cost of $1.5 billion. But through the launch, Sanofi hopes to recoup all of that expense--plus more.

Emory University researchers identify 'immune archive' in bone marrow

Researchers from Emory University have identified a set of long-lived antibody-producing cells in bone marrow. They function as a "catalog" of how an adult's immune system responded to measles or mumps viruses in childhood.

GSK, bioCSL to increase flu vaccine deliveries to U.S.

Early signs of the upcoming flu season came this week as three vaccine makers--GlaxoSmithKline, Sanofi Pasteur and bioCSL--announced their first shipments of flu shots for the 2015-16 season, with two reporting that they will increase the amount of doses they deliver.

Reuters: WHO, EMA likely to approve GlaxoSmithKline's malaria vaccine despite challenges

Final trial results reported in April showed that the efficacy of GlaxoSmithKline's investigational malaria vaccine wanes over time. But the candidate, dubbed RTS,S or Mosquirix, is the furthest along in the quest for a vaccine and so, may win WHO and EMA approval as the first vaccine against malaria.

Expect vaccines market to swell to $40B by 2020: Tufts CSDD

Two recently-published market analyses paint a picture of a competitive but growing vaccines field through 2020, with the newest report from Tufts University stating the industry is on track to post $40 billion in annual sales in 5 years.

GSK and J&J/Bavarian Nordic take Ebola candidates to Senegal, Europe

Although the waning Ebola outbreak had Big Pharmas struggling to find volunteers for their Ebola vaccine trials, two new Phase II trials are going forward. GlaxoSmithKline will take its candidate to Senegal, while Johnson & Johnson and partner Bavarian Nordic will test their vaccine in France and the U.K.

EMA to again place HPV vaccines under its safety lens

While the European Medicines Agency said it "does not question that the benefits of HPV vaccines outweigh their risks," on Monday it announced a safety review of the shots that have thus far failed to live up to expectations partly due to safety concerns and a sex-related stigma.

Shantha's cholera jab prevents 37% of cholera cases in Bangladeshi study

In a huge Bangladeshi trial, Shanchol, Shantha Biotechnics' affordable cholera vaccine, prevented almost 40% of cholera cases. When combined with increased hand-washing, the vaccine prevented 45% of cases.

Poll: Parents view vaccines as safer, more beneficial

A new national poll shows that parents' views on vaccines became more favorable between 2014 and 2015, the same period that multiple outbreaks of measles and whooping cough unrolled around the country.